Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Combination Drugs Are The Future for Hepatitis C
|
Steve Worland |
11/03/09 |
San Diego
|
|
Seattle Biotech Needs More Bars, Less University Red Tape, and the Same Daring Attitude, & Other Highlights from Seattle Life Sciences 2029
|
Luke Timmerman |
10/21/09 |
Seattle
|
|
How Biotechs Can Stand Out in the Competition for a Big Pharma Partnership
|
Peppi Prasit |
09/17/09 |
San Diego
|
|
Finding HIV’s Weak Spot, Scientists at Seattle’s Theraclone and San Diego’s Scripps See Opening for New Vaccine
|
Luke Timmerman |
09/03/09 |
National
|
|
Icahn Throws Down the Gauntlet, Attacks Biogen Idec’s “Failed Leadership”
|
Luke Timmerman |
05/11/09 |
Boston
|
|
Genzyme Offers Glimpse at Growth Engine, New Drugs for High Cholesterol, Gaucher’s
|
Luke Timmerman |
05/07/09 |
Boston
|
|
Antibodies for HIV, Long Dismissed, Show Signs of Comeback at Seattle’s Theraclone
|
Luke Timmerman |
04/07/09 |
Seattle
|
|
Obama Stimulates UW, Public Biotechs Run Low on Cash, Healionics Ships Glaucoma Product & More Seattle-Area Life Sciences News
|
Luke Timmerman |
03/26/09 |
Seattle
|
|
EU Spurns Gilead’s Aztreonam
|
Luke Timmerman |
03/20/09 |
Seattle
|
|
Amira’s Drug Discovery Team, Pioneers of Hit Asthma Treatment, Take Aim at Pulmonary Fibrosis
|
Luke Timmerman |
03/18/09 |
San Diego
|
|
What’s a Biotech Banker To Do in a Downturn? How About M&A
|
Luke Timmerman |
03/16/09 |
Seattle
|
|
Life Sciences on a Budget: Startups Make Pitch for Angel Dollars at First Zino Society Forum
|
Luke Timmerman |
02/25/09 |
Seattle
|
|
Out With Hedge Funds, In With Blue Bloods: Vertex Transforms Investor Base Via Stock Sale
|
Luke Timmerman |
02/20/09 |
Boston
|
|
Alkermes Knocks on Door of Biotech Big Leagues, Aims to Make Drugs of its Own
|
Luke Timmerman |
02/12/09 |
Boston
|
|
Hey, Don’t Forget the Puget Sound Life Sciences Universe!
|
Luke Timmerman |
02/09/09 |
Seattle
|
|
Seattle Genetics Defies Gravity With Biotech’s First Underwritten Stock Sale in Six Months
|
Luke Timmerman |
02/05/09 |
Seattle
|
|
Vertex Envisions a Single Massachusetts Campus and a Bold Future
|
Luke Timmerman |
01/15/09 |
Boston
|
|
Anadys Shares Boom on Hepatitis C Finding
|
Luke Timmerman |
01/08/09 |
San Diego
|
|
Hepatitis C Drug From Anadys Shows Quick Virus-Killing Punch
|
Luke Timmerman |
01/08/09 |
San Diego
|
|
Amgen Tries to “Personalize” Drug, VLST Snags Deal, Tobacco Money Backs Research, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
12/18/08 |
Seattle
|
|
Luck, Curiosity, Naivete: The Essential Ingredients of Innovation
|
Luke Timmerman |
12/16/08 |
Seattle
|
|
Traditional Venture Model is “Broken” for Biotech, Companies Need to Adapt, Says VC Alan Frazier
|
Luke Timmerman |
12/04/08 |
Seattle
|
|
ZymoGenetics CEO Bruce Carter Retires, Promotes Doug Williams, Says Sad Goodbyes to Biotech “Family”
|
Luke Timmerman |
11/21/08 |
Seattle
|
|
Microsoft’s Life Sciences Game Plan: Use IT to Usher in the World of Predictive, Personalized Medicine
|
Luke Timmerman |
11/13/08 |
Seattle
|
|
Prescription Drugs for Half the Price: Wellpartner Smooths Way for Clinics to Buy Them
|
Luke Timmerman |
11/05/08 |
Seattle
|
|
Aires Pharmaceuticals Emerges from Stealth Mode With Drug for Pulmonary Arterial Hypertension
|
Luke Timmerman |
11/05/08 |
San Diego
|
|
Anadys Drug Found Safe in Small Study, Aims to Contend in New Class of Hepatitis C Meds
|
Luke Timmerman |
11/01/08 |
San Diego
|
|
Gilead Signs Lease to Grow in Seattle, Despite Aztreonam Delay
|
Luke Timmerman |
10/23/08 |
Seattle
|
|
WRF Capital, With Clock Ticking on Expiring Patents, Aims to Build Sustained Venture Fund
|
Luke Timmerman |
10/20/08 |
Seattle
|
|
Concert Pharmaceuticals, Flush With Well-Timed Venture Round, Aims for Hot Flashes, HIV
|
Luke Timmerman |
10/14/08 |
Boston
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
